

Reduced-Immunogenicity Wheat and Peanut Lines for People with Foodborne Disorders [†]

Sachin Rustgi ^{*}, Tariq Alam, Zachary Tyler Jones, Amanpreet Kaur Brar and Samneet Kashyap

Department of Plant and Environmental Sciences, School of Health Research,
Clemson University Pee Dee Research and Education Centre, Florence, SC, USA

^{*} Correspondence: srustgi@clemson.edu

[†] Presented at the 1st International Online Conference on Agriculture—Advances in Agricultural Science and Technology (IOCAG2022), 10–25 February 2022; Available online: <https://iocag2022.sciforum.net/>.

Abstract: Sensitivity to wheat and peanut proteins is widespread and is not restricted to geographical areas where wheat and peanuts are produced. It emphasizes the importance of these crops as the source of energy and proteins to populations globally. An uptick in the number of individuals diagnosed with celiac disease, an autoimmune disorder - and peanut allergy was observed in the last two decades. According to a recent estimate, ~1.4% of the world population is diagnosed with celiac disease, and ~2% of the western population with peanut allergies. Unfortunately, there is no therapy available for these sensitivities other than an abstinent diet with a need to maintain an immunogen-free environment to prevent sensitive individuals' accidental exposure to the antigen. Given this knowledge, we focused our research on developing reduced-immunogenicity wheat and peanut genotypes that can significantly reduce the scope of severe reaction to accidental exposure to wheat/peanut proteins. Working in this direction, we undertook two approaches to develop reduced-immunogenicity wheat/peanut genotypes: (1) wheat/peanut germplasm screening for genotypes with reduced immunogen content to crossbreed them to develop reduced to non-immunogenic wheat/peanut lines. (2) Use genetic engineering to silence genes encoding immunogenic proteins. To achieve the first objective, we screened wheat landraces/mutants and peanut-mini-core collections. Similarly, for gene silencing, RNA interference constructs for wheat *DEMETER* gene or guide RNAs from the wheat gluten gene sequences and the peanut *Ara h1*, *Ara h2*, *Ara h3*, and *Ara h6* gene sequences were developed and assembled in single guide RNA modules. The progress made towards the target is discussed below.

Keywords: celiac disease; allergy; wheat; peanut; gluten; non-celiac gluten sensitivity

Citation: Rustgi, S.; Alam, T.; Jones, Z.T.; Brar, A.K.; Kashyap, S. Reduced-Immunogenicity Wheat and Peanut Lines for People with Foodborne Disorders. *Chem. Proc.* **2022**, *4*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor(s):

Published: date

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Sensitivity to wheat and peanut proteins is more common than initially thought and is not restricted to geographical areas where wheat and peanuts are produced (Figure 1). It reflects on the widespread consumption and importance of these crops as the source of energy and proteins. Specifically, wheat is grown over 15.5% of the world's arable land (World—Wheat area harvested 2020), provides dietary calories to 35% of the population, and feeds one-quarter of the global annual demand for dietary plant proteins (Grote et al. 2021). Similarly, the peanut is cultivated over 3% of the world's arable land (Putnam et al. 1991), and its oil (50% by weight) and protein (25% by weight) rich kernels meet the protein needs of many worldwide, more specifically, the poor, earning it the reputation of 'poor man's nut' (Ozias-Akins and Breiteneder 2019; Shah et al. 2019; Prema 2015). These two crops are vital for low and middle-income countries and countries with large vegetarian and vegan populations (375 million individuals globally). Also, these crops are a significant component of the export profiles of the industrialized countries.




Figure 1. Figure from left to right showing the geographical distribution of the peanut and wheat production areas and where they are consumed. Figures on the extreme right show the geographical distribution of food allergies (top, primarily represented by peanut allergies) and celiac disease.

Unfortunately, an uptick in the number of individuals diagnosed with celiac disease, a wheat-associated autoimmune disorder—and peanut allergy was observed in the last two decades. According to a recent estimate, ~1.4% of the world population is diagnosed with celiac disease and ~2% of the Western population with peanut allergy (Singh et al. 2018; Warren et al. 2021). Tragically, there is no therapy available for these sensitivities other than an abstinent diet with a need to maintain an immunogen-free environment to prevent sensitive individuals' accidental exposure to the antigen (Rustgi et al. 2019; Shah et al. 2019). Following a gluten-free or peanut-free diet is a formidable task due to the ubiquitous presence of wheat and peanuts in processed food, cosmetics, and even medicines, social and economic reasons (Brouns et al. 2019; Shah et al. 2019). Thus, making it essential to stay vigilant at all times, specifically in the case of children who are disproportionately affected by peanut allergies. However, an individual can develop sensitivities to wheat and peanut later during life for several reasons, including changes in the lifestyle leading to alterations in the gut microbiome. Also, maintaining a gluten-free or peanut-free environment accommodating all individuals irrespective of their dietary restrictions is economically taxing.

Sensitivity to wheat can be classified into three kinds: i) Celiac disease—a chronic disorder triggered by wheat gluten and allied proteins from related cereals like barley and rye; it could develop into an autoimmune disorder if it remains untreated. ii) Gluten allergy—an instant reaction to gluten exposure. iii) Non-celiac wheat sensitivity—a less well-understood reaction to wheat and wheat products (Sapone et al. 2012; Brouns et al. 2019). However, exposure to the peanut causes an instant allergic reaction in genetically predisposed individuals, which could vary in the severity of response in different individuals allergic to peanut (Shah et al. 2019). Primarily in peanut and wheat sensitivities, the trigger for these reactions is indigestible proteins. A large family of proteins (~100 members) known as gluten in wheat (Rustgi et al. 2019; Shewry 2019) and about 16 seed storage proteins in peanuts were recognized to trigger immune reactions in humans (Shah et al. 2019). Among wheat gluten proteins, gliadins (α/β , γ , and ω), and peanut seed storage proteins, Ara h1, Ara h2, Ara h3, and Ara h6 were identified as major immunogens (Rustgi et al. 2019; Shah et al. 2019).

2. Peanut Allergy

As mentioned earlier, peanuts are among the nine primary sources of food allergy recognized by the US Food and Drug Administration (US Food & Drug Administration 2021), which, along with tree nuts, are responsible for 90% of allergy-related fatalities

(Shah et al. 2019). Epidemiological studies show peanut allergy affects about 6.1 million children and adults in the US (Food Allergy Research & Education 2022). In the last two decades, peanut allergy diagnoses have risen from 0.4% (1997) to 1.8% (2021) of the population, and the number is escalating (Warren et al. 2021). Raw peanuts and derived products lead to various allergic responses, the most common being immediate-onset anaphylaxis. Peanut allergy currently requires the complete exclusion of peanuts from the diet (Shah et al. 2019). Avoiding peanuts, other cross-reacting tree nuts, and legumes limit the options to obtain proteins. Also, avoiding the peanut is not straightforward due to its ubiquitous presence in processed foods, unintended contamination, financial and social constraints. Sixteen proteins in peanut grains, namely Ara h1 to Ara h17 (Ara h4 is now characterized as an isoform of Ara h3 and renamed Ara h3.02), were recognized as allergens. Four proteins, Ara h1, Ara h2, Ara h3, and Ara h6, were identified as major allergens, as sera from 50% of patients respond to these allergens (Shah et al. 2019).

Several efforts are underway to develop dietary alternatives, i.e., reduced immunogenicity peanuts and therapies for peanut-sensitive individuals (Shah et al. 2019; Vickery et al. 2018). These efforts vary significantly in the pursued approaches, such as physical (thermal processing, high-pressure processing, irradiation, electrical discharge, and ultrasonication) and chemical (chemical modification and enzyme processing) treatments of peanut kernels (Shah et al. 2019) and genetic strategies to develop reduced-immunogenicity peanut genotypes (Konan et al. 2009; Dodo et al. 2008; Chu et al. 2008). In parallel, efforts are underway to develop therapies for peanut allergy, in addition to a recently released vaccine (Palforzia™; Vickery et al. 2018).

We undertook the genetics approach to address this problem from a prevention standpoint, unlike many previous attempts that focused on processing methods or therapeutics via developing reduced immunogenicity peanut genotypes following a molecular breeding approach. These genotypes would serve several purposes: (1) Reduce the risk of an intense immune reaction in sensitive individuals upon accidental exposure. (2) If administered under observation, these genotypes could act as a booster for the peanut allergy vaccine recently approved by the U.S. Food and Drug Administration (Vickery et al. 2018). (3) These peanuts could also facilitate building resistance against peanut allergens at an early age if consumed under guidance (Couzin-Frankel, 2018). Additionally, these genotypes would help the community by reducing the financial burden in maintaining a peanut-free environment, keeping the number of hospitalizations low, and the need for emergency treatments, such as epinephrine/adrenaline injection.

2.1. Peanut Germplasm Screening for Reduced Content of Immunogenic Proteins

In a screen of peanut germplasm (including USDA and ICRISAT peanut mini-core collections and a set of South Asian lines) for reduced immunogen content, we identified several *Arachis hypogaea* genotypes and an *Arachis diogeni* line GKP 10602 that can serve as a source of reduced immunogenicity trait, as these genotypes exhibited deficiency in several immunogenic proteins (Figure 2). *A. diogeni* is a diploid wild peanut species similar to the 'A' sub-genome of cultivated peanut (*A. hypogaea*). Also, *A. diogeni* was earlier identified as a source of pest and disease resistance, specifically early and late leaf spot and tomato spotted wilt virus, to name a few (Stalker 2017), and hence deployed to develop a unique *A. hypogaea* (Virginia-type peanut cultivar 'Gregory') × *A. diogeni* (accession GKP 10602) introgression population (Hancock et al. 2019). This population of 84 introgression lines was characterized using DNA markers, and introgressions of *A. diogeni* chromatin in *A. hypogaea* chromosomes were identified. These introgressions measured about 3.00 to 18.14% of individual *A. hypogaea* chromosomes and involved both peanut sub-genomes (Hancock et al. 2019). A preliminary analysis of introgression lines for their seed storage protein profiles revealed the inheritance of reduced-immunogenicity trait from diploid parent to tetraploid progeny (recorded as missing protein bands) (Figure 2). These observations led us to hypothesize that it is possible to identify tetraploid (similar to cultivated peanut) peanut lines with the level of immunogenic proteins similar to the diploid parent,

A. diogeni. Also, since this population is genotyped heavily with a 48K single nucleotide polymorphism (SNP) array, it is possible to map the locations of genes/Protein Quantity Loci that regulate variation in the content of immunogenic proteins and identify DNA markers associated with reduced content of immunogenic-proteins to facilitate transfer and breeding for this trait. Since different genotypes lacked different immunogenic proteins, it is possible to stack their protein phenotypes via a strategically planned genetic crossing scheme and selection with protein and DNA markers.




Figure 2. Protein profiles of peanut genotypes with reduced content of immunogenic proteins Ara h1, Ara h2, Ara h3, and Ara h6. Selected genotypes of the USDA and ICRISAT mini-core collections with reduced content of major immunogenic proteins studied using enzyme-linked immunosorbent assay (ELISA) (A, top). SDS-PAGE gel showing selected genotypes of the South Asian collection lacking Ara h1, Ara h3, and Ara h6 completely or accumulating a reduced amount of different immunogenic proteins (A, bottom). High-performance liquid chromatograms of seed storage proteins extracted from peanut cultivar ‘Gregory’ and *Arachis diogeni* accession GKP 10602 (identified from the screen for reduced immunogenicity lines) (B, top). Notice the significant reduction in the HPLC peak area in GKP 10602 at corresponding elution times compared to Gregory (pay attention to the scale on the y-axis). Protein profiles of Gregory and GKP 10602 and the interspecific hybrid population derived from their genetic cross (only selected introgression lines shown). Notice the missing protein bands and the differences in the intensity of different protein bands (B, bottom). M = pre-stained protein marker.

2.2. Peanut Genetic Engineering for Reduced Content of Immunogenic Proteins

In parallel to the germplasm screening, we started efforts to edit out major allergenic proteins from the peanut genome. It required the development of genomic editing reagents for multi-gene editing in peanuts and the gene-delivery methods, specifically those leading to the non-transgenic end product. Eliminating allergenic proteins from the peanut genome is complex due to its polyploid nature. As mentioned earlier, out of the 16 known allergenic proteins, four, Ara h1, Ara h2, Ara h3, and Ara h6, are major allergens. Genes for these major allergens map to 6 peanut chromosomes belonging to three homoeologous chromosome groups. We pulled out sequences of these genes from the public domain, clustered them, and used them for online identification of LbCas12a target sites per gene family for genome editing using a CRISPR-based multi-gene editing approach (Windham et al. 2021). Before developing the construct for the delivery of the genome-editing reagents, we tested each of these gRNAs in vitro, and the ones performing as desired were assembled in the guide RNA module. We developed two constructs, one each for the biolistic delivery in the peanut embryo-derived calli and the virus-mediated delivery to intact plants. We are using both of these methods to develop peanut lines with reduced content of immunogenic proteins with some initial success.

A somewhat similar effort by other groups, such as two startups, Aranex and IngateyGen, is to target Ara h1, Ara h2, or Ara h3, or all three genes via the CRISPR approach are underway. Whereas, Ukko, another startup, is trying to develop engineered peanut proteins for oral immunotherapy. On the other hand, little research has been undertaken so far on the conventional solutions by looking at natural genetic diversity, except for a recent study from ICRISAT, India (Pandey et al. 2019), where they identify some peanut genotypes reduced in one or more of major allergens.

2.3. Wheat Sensitivity (Celiac Disease, Wheat Allergy, and Non-Gluten Wheat Sensitivity)

Gluten proteins, technically known as prolamins, are the major seed storage proteins in the wheat grains that are also one of the most consumed dietary proteins in the world. On the flip side, unfortunately, gluten is also the primary source of several wheat-associated dietary disorders (Sapone et al. 2012). According to an estimate, about 1.4% of the world population is affected by celiac disease, and even a larger proportion by wheat allergy and non-gluten wheat sensitivity (Singh et al. 2018). The only effective therapy is lifelong adherence to an abstinent diet, devoid of wheat and related cereals, such as barley and rye, and hybrid cereals like Triticale and Tritordeum (Brouns et al. 2019). However, this diet is difficult to follow due to the same reasons as discussed for the peanut (Osorio et al. 2012, 2019a). Moreover, this solution is associated with penalties, for instance, i) strict adherence to a diet totally devoid of gluten-containing grains deteriorates gut health by its negative influence on the gut microbiota, and ii) long-term adherence to carbohydrate-rich gluten-free diet results in multiple deficiencies and change in patient's body mass index (BMI) (Rustgi et al. 2019). Therefore, the gluten-free diet is only recommended to individuals with medically proven gluten sensitivity (Diez-Sampedro et al. 2019).

No extant wheat genotype under cultivation or in the wild is safe for celiac patients (Rustgi et al. 2019, 2020a, 2021). Therefore, in order to develop celiac safe wheat cultivars, we undertook two approaches genetic engineering and germplasm screening. The latter approach consists of two different strategies: (i) Epigenetic elimination of gliadins and low molecular weight glutenins by silencing of the wheat genes encoding a DNA glycosylase *DEMETER* and an iron-sulfur biogenesis enzyme *Dre2*, which are responsible for transcriptional de-repression of prolamins genes in the developing endosperm (Wen et al. 2012; Mejias et al. 2014; Rustgi et al. 2014, 2020b; Wen et al. 2022) and (ii) post-translational detoxification of 'gluten' proteins by ectopic expression of glutenases in wheat endosperm (Osorio et al. 2019b, 2020).

2.4. Wheat Genetic Engineering for Reduced-Gluten Content and to Express Glutenases in Grains

Since gluten is a complex mixture of about 100 proteins encoded by a large number of genes, we devised a clever strategy to deal with this problem by silencing a master regulator of prolamins accumulation in wheat grains (Wen et al. 2012). This strategy is based on the fact that there are two categories of promoters for endosperm specific gene expression: one that are silenced by methylation in vegetative tissues and must be demethylated before transcription in endosperm, and the other depends solely on the removal of repressors or induction of endosperm-specific transcription factors (Wen et al. 2012). In wheat, the promoters of LMWGs and gliadins belong to the first category and the promoters of HMWGs belong to the second category (Wen et al. 2012). It suggests that similar to a high lysine barley mutant Risø 1508, the gliadins and LMW glutenin subunits in wheat can be eliminated by epigenetic regulation without affecting the synthesis of HMW glutenin subunits, which are indispensable for baking and are largely non-immunogenic (Wen et al. 2012).

Given *DEMETER*'s vital role in pollen development in *Arabidopsis* (Schoft et al. 2011; Khouider et al. 2021) and in wheat (see below), we adapted an RNA interference-based method for tissue specific silencing of the *DME* gene. For this purpose, a 938 bp hairpin

with a 185 bp stem and a 568 bp loop was synthesized and cloned under the control of the wheat HMWgs promoter. The construct was used for biolistic transformation of wheat scutellar calli and 118 putative transformants were obtained. Out of these 118 candidates, only 7 plants exhibited 45–76% reductions in the amount of immunogenic prolamins (Wen et al. 2012). Interestingly, these transformants showed reductions in amount of different prolamins. As hairpin construct could lead to off targeting of genes, we designed miRNA from the active site and the N-terminal region of the wheat *DEMETER* homoeologues. Three amiRNA sequences were selected and assembled on rice MIR528 template using overlapping primers and cloned with the wheat HMWgs promoter. The constructs were delivered to wheat via biolistic approach. The selection scheme yielded a total of 215 candidate transformants and 39 lines showing transgene integrations. Out of these 39 putative transformants 12 lines showed 40–75% reduction in the amount of immunogenic prolamins (Figure 3A) (Rustgi et al. 2014; Mejias et al. 2014). Protein profiling of these transformants exhibited elimination of specific prolamins and/or prolamin groups. Additionally, these lines showed many desirable characteristics such as compensatory increases in the amount of HMW glutenin subunits, albumins and globulins, increased grain lysine content, and gluten strength (Rustgi et al. 2019).




Figure 3. Genetically engineered wheat with reduced-gluten content (A) and expressing ‘glutenases’ in the wheat endosperm (B). Polyacrylamide gel electrophoresis of gliadins (top) and glutenin (bottom) fractions extracted from the grains of the 12 selected genetically engineered wheat line (A). Differences in the degradation patterns of gluten proteins derived from a transgenic wheat line expressing *Flavobacterium meningosepticum* prolyl endopeptidase (FME108-10) and its untransformed sibling (FME108-12) under simulated gastro-intestinal conditions with endoprotease B isoform 2 (EP-B2) (B). Gradient tricine gel and densitometric analyses of the digested gliadin fraction derived from FME108-12 with no EP-B2 (left lane and trace), FME108-12 with EP-B2 (middle lane and trace), and FME108-10 with EP-B2 (right lane and trace) (a). Reversed-phase high-performance liquid chromatography of gluten proteins derived from the T₂ grains of FME108-12 with EP-B2 (blue line) and FME108-10 with EP-B2 (red line) on a C18 column (b) (modified after Rustgi et al. 2021).

To develop a dietary therapy for celiac patients we decided to express glutenases in wheat endosperm (Rustgi et al. 2014; Osorio et al. 2019, 2020). Based on the parameters like target specificity, substrate length, optimum pH, and site of action a prolyl endopeptidase from *Flavobacterium meningosepticum* and a glutamine specific endoprotease from barley were selected for expression in wheat endosperm (Osorio et al. 2019). Wheat transformants expressing these glutenases were obtained, and a few transformants exhibited

significant reductions in amount of indigestible gluten peptides on the tricine PAGE gels and RP-HPLC (Figure 3B) (Osorio et al. 2019). The wheat grains expressing 'glutenases' are expected to benefit all consumers due to improved bioavailability of storage proteins.

2.5. Wheat Germplasm Screening for Reduced-Gluten Content

Thirty-four wheat landraces and 27 ABA-biosynthesis or hypersensitive mutants (ABH) and ABA-signaling or insensitive mutants (ABI) were tested for their protein profiles using SDS-PAGE-based densitometric analysis and high-performance liquid chromatography (Rustgi et al. 2020c). Gluten-banding patterns from the genotypes of a landrace or across landraces were compared, and the mutant types were identified. Mutants with different missing gluten proteins were selected for the genetic crossing to stack their effects on gluten content in a single genotype. The differences in the banding pattern observed in these genotypes were divided into two categories: qualitative differences and quantitative differences. The deficiency of a protein subunit (qualitative differences) was determined by comparing the protein profile of different genotypes of a landrace (analyzed three to four half-seeds per landrace). On the other hand, the quantitative differences were determined via densitometric analysis of corresponding bands (determined based on molecular weights) among genotypes belonging to a landrace. Similar criteria were used to study quantitative and qualitative differences in protein profiles of the wheat ABA insensitive and hypersensitive mutants, except, in this case, comparisons were made with the respective wild type controls (Rustgi et al. 2020c).

Based on the knowledge that the enzyme coded by the wheat *DEMETER* gene is responsible for the transcriptional activation of the gluten genes in developing wheat grains (Wen et al. 2012), we screened two TILLING populations one each in 'Kronos' and 'Express' backgrounds, for mutations in the *DEMETER* genes (Rustgi et al. 2014; Wen et al. 2022). To reduce the workload, we confined our search for the mutants to one kb region in the active site of the *DEMETER* genes. Screen for mutations in 'Kronos' and 'Express' populations respectively yielded 77 and 149 mutations. The single mutations in *DEMETER* homoeologues showed reductions in specific prolamins (Wen et al. 2022). Crosses were made between the mutants carrying substitutions, premature stop codons, and splice site variations in A and B sub-genome *DEMETER* homoeologues to pyramid the effect of the individual mutations in a single genotype. Unfortunately, the crosses between the mutants carrying premature stop codons or splice site variations never yielded a double mutant (Rustgi et al. 2014; Wen et al. 2022). To determine the cause of the observed segregation distortion, we closely monitored the anther morphology, the number of viable pollens, and pollen germination. We observed, the nonsense mutations in wheat *DEMETER* genes have significantly reduced the anther locule size, the number of viable pollen, and negatively affected the pollen germinate. Thus, this analysis also suggested a vital role of *DEMETER* in pollen development and germination (Rustgi et al. 2014, 2020c; Wen et al. 2022).

The Dre2 or Derepressed for Ribosomal protein S14 Expression facilitates the deposition of the iron-sulfur (Fe-S) cluster to the *DEMETER* apoenzyme, which is vital for its interaction with genomic DNA and its subsequent demethylation (Buzas et al. 2014). Given Dre2's role in *DEMETER* activation, we decided to test its effect on prolamins accumulation (Rustgi et al. 2020c). As a first step, the TILLING population in 'Kronos' background was screened for mutations in the wheat *Dre2* homoeologues. Thirteen mutants in the 2AL copy and three mutants in the 2BL copy of the *Dre2* gene were identified (Rustgi et al. 2020c; Wen et al. 2022). The single mutations in the *Dre2* homoeologues showed reductions in specific prolamins. These single mutations are currently being crossed in the greenhouse to pyramid their effects. During these attempts, it was continuously noticed that the anther size for the Dre2-2AL mutants was significantly smaller than the wild type control (Wen et al. 2022).

Similar efforts are underway in different parts of the world to develop reduced-immunogenicity wheat genotypes suitable for celiac patients and wheat allergic individuals

(Rustgi et al. 2019, 2020a, 2021; Wang et al. 2020). Some noteworthy efforts from the public sector were from the Francisco Barro's group at the Institute for Sustainable Agriculture, Córdoba, Spain, Susan Altenbach's group at the Western Regional Research Center, USDA-ARS, Albany, CA, Hetty van den Broeck's, and Marinus Smulders's group at Wageningen University & Research, Netherlands, and Domenico Lafiandra's group at the University of Tuscia, Italy. Similar remarkable efforts are underway in the private sector at Calyxt, Roseville, Minnesota, Arcadia Biosciences, Davis, CA, and the Bayer-supported startup Ukko, Rehovot, Israel. The earlier efforts primarily focused on pyramiding the reduced gluten wheat mutants (natural and induced) and the later on genetic engineering (including RNA interference and gene editing). However, different efforts differed in the genes targeted and the adopted strategies. For instance, some focused on editing the specific motifs (epitopes) in gluten proteins rather than eliminating them. Recently, via their persistent efforts, Barro and co-workers demonstrated that a reduced gliadin RNAi line (E82) did not elicit an immune response in celiac patients under a pilot blind randomized crossover gluten challenge (Guzmán-López et al. 2021). It gives hope that the reduced-immunogenicity wheat genotypes in the pipeline will turn helpful to celiac patients.

3. Public Perspective

We focus on developing reduced-immunogenicity wheat and peanut genotypes that can significantly reduce the scope of severe reaction to accidental exposure to wheat/peanut proteins. However, one major question that we often encounter is the need for reduced immunogenicity crops while gluten-/peanut-free products are already an option. There are several reasons to pursue this line of research: (i) for many in low-income countries, a gluten/peanut-free diet is not an option due to the unavailability of these products or financial reasons. Particularly, in the case of sustenance farmers, who also are limited by choice of crops they can grow, either due to market-driven reasons or adaptability of crops in their region. (ii) Removing cereals (wheat, barley, and oats) or peanuts from the diet deprives the consumer of many other essential nutrients, such as fibers, antioxidants, vitamins, and minerals. Indeed, several recent studies suggested that removing wheat from the diet, in the long run, enhances the risk of developing colorectal cancer due to deficiency of the fermentable fibers and essential phenolic compounds from the diet, and long-term adherence to a gluten-free diet increases the chances of adverse changes in the body mass index and composition of gut microbiota (Rustgi et al. 2019; Rustgi et al. 2021). Further, removing wheat and peanut and the cross-reacting grains from diet limits vegetarians' and vegans' options to get the required level to dietary proteins. On the other hand, the reduced immunogenicity genotypes of wheat and peanuts could bring back the balance in the lives of individuals with wheat/peanut sensitivities, who are forced to remove these grains/nuts from their diets under the current regimen. As mentioned earlier, these genotypes will retain conventional wheat and peanut benefits while not triggering an immune reaction. Additionally, these genotypes will reduce the risk of accidental exposure to allergens and, upon exposure, a severe response, lowering consumers' financial burden. Especially in a vegetarian/vegan diet, limited by choice, these genotypes will reintroduce the option of incorporating wheat and peanut. Further, these reduced immunogenicity lines can be effectively utilized to develop early immunity in children and even adults in supervised settings, specifically the individuals vaccinated for peanut allergy. Under controlled settings and after necessary testing, the measured doses of reduced-immunogenicity wheat/peanut genotypes could be administered as vaccines.

Another big question that often arises is the fear of spoiling the wheat's and peanut's palatability/texture, nutritional quality, processing attributes, or field performance by making alterations in their protein composition. The earlier studies addressed it to some extent. For instance, Jianmei Yu and co-workers treated roasted/raw peanut kernels with a cocktail of digestive enzymes. The process solubilized (removed) 100% Ara h1 and 98% Ara h2 proteins and essentially produced Ara h1 and Ara h2 free peanut kernels (Yu et al., 2011). After analysis, the authors of this work concluded that the enzymatic removal

of immunogenic proteins produces hypoallergenic kernels without an adverse effect on peanut's nutritional quality and flavor. In another study, using RNA interference, Hortense Dodo and group silenced three major allergen genes Ara h1, Ara h2, and Ara h3 (Konan et al. 2009). This study concluded that the transgenic line significantly reduced in Ara h1, Ara h2, and Ara h3 content is at par in its agronomical performance and end-use quality to the untransformed control. After field testing, this line was named 'Serenity' and is nearing its release later this year. However, the genotype being transgenic, its public acceptance is debatable. Further, Peggy Ozias-Akins and co-workers demonstrated that contrary to the suspicion, the suppression of Ara h2 (a trypsin inhibitor) and Ara h6 did not render peanut susceptible to soil-born fungi, *Aspergillus* spp., indicating that elimination of immunogenic proteins from peanut kernels is a viable approach (Chu et al. 2008). In peanuts, Ara h1, Ara h2, and Ara h3 cumulatively represent 30% of the total seed proteins (Chassaigne et al. 2007), where Ara h1 constitutes 12–16% of it and Ara h2 6–9% (Shah et al. 2019). Ara h6 accounts for only a tiny amount of grain proteins. To sum up, the major allergens constitute about 30% of the grain proteins, and based on the existing knowledge we anticipate that other proteins or free amino acids would compensate for their loss; hence we don't expect these changes to reduce the peanut nutritional quality or flavor.

Similar studies were performed in wheat. These studies suggested that eliminating proteins from the wheat grains does not lead to a gross reduction in the protein content and it generally stays the same as other proteins compensate for the loss (Rustgi et al. 2019). Further, studies were performed in different market classes of wheat to determine the effects of eliminating specific glutenins and gliadins on their end-use performance. For instance, Kieffer and co-workers demonstrated that it was possible to bake a bread with reasonable crumb and crust structures after eliminating all gluten except HMW subunits from wheat flour. This was shown by baking bread from a mixture of the washed-out wheat flour residues (containing starch, soluble protein, fat, fibre, and minerals) and known quantities of recombinant HMW subunits (1Dx5 and 1Dy10). The dough kneaded from the mixture showed good elasticity and after baking resulted in bread rolls with reasonable volume and internal structure (Kieffer et al. 2007). Similar conclusions were reached when the flour derived from wheat transformants lacking one or more families of the gluten proteins were baked into normal looking loaves with acceptable organoleptic properties (Gil-Humanes et al. 2014). Additionally, authors of this study reported that silencing the glutamine and proline rich gluten proteins from the wheat grains consequently increases grain lysine content due to the compensation of the missing gluten proteins via more balanced albumins and globulins and free amino acids. An observation which was concurred by the high lysine barley mutants (*lys3a* and *lys1*), which exhibit reduced hordein (gluten homolog in barley) content (Rustgi et al. 2019, 2021). Collectively, these studies suggested that deletions in genes encoding different gluten proteins in generally bake into bread/cookies with reasonable textural and organoleptic properties. Additionally, further improvement in the functional properties of reduced-gluten wheat flours could be achieved by blending them with the proteins of non-toxic cereals or non-cereals (Rustgi et al. 2019, 2021).

Acknowledgments: This work was supported by grants from Clemson University (Clemson Faculty Succeeds Grant), National Institute of Food and Agriculture (NIFA Multi-state grant S009), SC Peanut Board, National Peanut Board, Foundation for Food & Agriculture Research (FFAR), Life Sciences Discovery Fund (LSDF), and National Institutes of Health (NIH).

References

1. Brouns, F.; van Rooy, G.; Shewry, P.; Rustgi, S.; Jonkers, D. Adverse reactions to wheat or wheat components. *Compr. Rev. Food Sci. Food Saf.* **2019**, *18*, 1437–1452.
2. Buzas, D.M.; Nakamura, M.; Kinoshita, T. Epigenetic role for the conserved Fe-S cluster biogenesis protein AtDRE2 in *Arabidopsis thaliana*. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 13565–13570.

3. Chassigne, H.; Nørgaard, J.V.; Hengel, A.J. Proteomics-based approach to detect and identify major allergens in processed peanuts by capillary LC-Q-TOF (MS/MS). *J. Agric. Food Chem.* **2007**, *55*, 4461–4473.
4. Chu, Y.; Faustinelli, P.; Ramos, M.L.; Hajduch, M.; Stevenson, S.; Thelen, J.J.; Maleki, S.J.; Cheng, H.; Ozias-Akins, P. Reduction of IgE binding and nonpromotion of *Aspergillus flavus* fungal growth by simultaneously silencing Ara h 2 and Ara h 6 in peanut. *J. Agric. Food Chem.* **2008**, *56*, 11225–11233.
5. Couzin-Frankel, J. Toxin or treatment? *Science* **2018**, *362*, 278–282.
6. Diez-Sampedro, A.; Olenick, M.; Maltseva, T.; Flowers, M. A gluten-free diet, not an appropriate choice without a medical diagnosis. *J. Nutr. Metab.* **2019**, *2019*, 2438934.
7. Dodo, H.W.; Konan, K.N.; Chen, F.C.; Egnin, M.; Viquez, O.M. Alleviating peanut allergy using genetic engineering: The silencing of the immunodominant allergen Ara h 2 leads to its significant reduction and a decrease in peanut allergenicity. *Plant Biotechnol. J.* **2008**, *6*, 135–145.
8. Food Allergy Research & Education. 2022. Available online: <https://www.foodallergy.org/resources/facts-and-statistics> (accessed on February 16, 2022).
9. Gil-Humanes, J.; Pistón, F.; Altamirano-Fortoul, R.; Real, A.; Comino, I.; Sousa, C.; Rosell, C.M.; Barro, F. Reduced-gliadin wheat bread: An alternative to the gluten-free diet for consumers suffering gluten-related pathologies. *PLoS ONE* **2014**, *9*, e90898.
10. Grote, U.; Fasse, A.; Nguyen, T.T.; Erenstein, O. Food security and the dynamics of wheat and maize value chains in Africa and Asia. *Front. Sustain. Food Syst.* **2021**, *4*, 617009.
11. Guzmán-López, M.H.; Sánchez-León, S.; Marín-Sanz, M.; Comino, I.; Segura, V.; Vaquero, L.; Rivero-Lezcano, O.M.; Pastor, J.; Sousa, C.; Vivas, S.; et al. Oral consumption of bread from an RNAi wheat line with strongly silenced gliadins elicits no immunogenic response in a pilot study with celiac disease patients. *Nutrients* **2021**, *13*, 4548.
12. Hancock, W.; Tallury, S.P.; Isleib, T.; Chu, Y.; Ozias-Akins, P.; Stalker, T. Introgression analysis and morphological characterization of an *Arachis hypogaea* × *A. diogeni* interspecific hybrid derived population. *Crop. Sci.* **2019**, *59*, 640–649.
13. Khoudier, S.; Borges, F.; LeBlanc, C.; Ungru, A.; Schnittger, A.; Martienssen, R.; Colot, V.; Bouyer, D. Male fertility in *Arabidopsis* requires active DNA demethylation of genes that control pollen tube function. *Nat. Commun.* **2021**, *12*, 1–10.
14. Kieffer, R.; Wieser, H.; Bauer, I.; Hoffmann, R.; Meuser, F. Functionality of glutenin subunits produced by transgenic yeast. In *Gluten Proteins 2006*; Lookhart, G.L., Ng, P.K.W., Eds.; AACCC International: St. Paul, MN, USA, 2007; pp. 54–57.
15. Konan, K.N.; Ananga, A.O.; Dodo, H. Reducing peanut allergy risks by means of genetic modification. In *Modification of Seed Composition to Promote Health and Nutrition*; Krishnan, H., Ed.; Agronomy Monograph 51: Madison, WI, USA, 2009; pp. 289–302.
16. Mejias, J.H.; Lu, X.; Osorio, C.; Ullman, J.L.; von Wettstein, D.; Rustgi, S. Analysis of wheat prolamins, the causative agents of celiac sprue, using reversed phase high performance liquid chromatography (RP-HPLC) and matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS). *Nutrients* **2014**, *6*, 1578–1597.
17. Osorio, C.; Wen, N.; Gemini, R.; Zemetra, R.; von Wettstein, D.; Rustgi, S. Targeted modification of wheat grain protein to reduce the content of celiac causing epitopes. *Funct. Integr. Genom.* **2012**, *12*, 417–438.
18. Osorio, C.E.; Mejias, J.H.; Rustgi, S. Gluten detection methods and their critical role in assuring safe diets for celiac patients. *Nutrients* **2019**, *11*, 2920.
19. Osorio, C.E.; Wen, N.; Mejias, J.H.; Liu, B.; Reinbothe, S.; von Wettstein, D.; Rustgi, S. Development of wheat genotypes expressing a glutamine-specific endoprotease from barley and a prolyl endopeptidase from *Flavobacterium meningosepticum* or *Pyrococcus furiosus* as a potential remedy to celiac disease. *Funct. Integr. Genom.* **2019**, *19*, 123–136.
20. Osorio, C.E.; Wen, N.; Mejias, J.H.; Mitchell, S.; von Wettstein, D.; Rustgi, S. Directed-mutagenesis of *Flavobacterium meningosepticum* prolyl-oligopeptidase and a glutamine-specific endopeptidase from barley. *Front. Nutr.* **2020**, *7*, 11.
21. Ozias-Akins, P.; Breiteneder, H. The functional biology of peanut allergens and possible links to their allergenicity. *Allergy* **2019**, *74*, 888–898.
22. Pandey, A.K.; Sudini, H.K.; Upadhyaya, H.D.; Varshney, R.K.; Pandey, M.K. Hypoallergen peanut lines identified through large-scale phenotyping of global diversity panel: Providing hope toward addressing one of the major global food safety concerns. *Front. Genet.* **2019**, *10*, 1177.
23. Prema, H.S. Seven ways to incorporate groundnuts into your daily meal. 2015. Available online: <https://economictimes.indiatimes.com/magazines/panache/seven-ways-to-incorporate-groundnuts-into-your-daily-meal/articleshow/50228959.cms?from=mdr> (accessed on February 16, 2022).
24. Putnam, D.H.; Oplinger, E.S.; Teynor, T.M.; Oelke, E.A.; Kelling, K.A.; Doll, J.D. Peanut. 1991. Available online: <https://hort.purdue.edu/newcrop/afcm/peanut.html> (accessed on February 16, 2022).
25. Rustgi, S.; Kashyap, S.; Alam, T.; Kerr, R.; Jones, Z.; Naveed, S.; Shekar, P.V.; Gemini, R.; Reisenauer, P. Non-immunogenic wheat needed to feed 10% of the US population suffering from wheat-related disorders. *Ann. Wheat Newslet.* **2020**, *66*, 93–98.
26. Rustgi, S.; Kashyap, S.; Ankrah, N.; von Wettstein, D. Use of microspore-derived calli as explants for biolistic transformation of common wheat. In *Biolistic DNA Delivery in Plants*; Rustgi, S., Luo, H., Eds.; Springer Nature: New York, NY, USA, 2020; pp. 263–279.
27. Rustgi, S.; Kashyap, S.; Deleu, L.J.; Delcour, J. Reduced-immunogenicity wheat now coming to age. In *Physiological, Molecular, and Genetic Perspectives of Wheat Improvement*; Wani, S.H., Mohan, A., Singh, G.P., Eds.; Springer Nature, Cham, Switzerland, 2021; pp. 279–300.

28. Rustgi, S.; Shewry, P.; Brouns, F. Health hazards associated with gluten consumption in susceptible individuals and current status of research on the dietary therapies. In *Wheat Quality for Improving Processing and Human Health*; Igrejas, G., Ikeda, T.M., Guzmán, C., Eds.; Springer, Cham, Switzerland, 2020; pp. 471–515.
29. Rustgi, S.; Shewry, P.; Brouns, F.; Deleu, L.J.; Delcour, J.A. Wheat seed proteins: Factors influencing their content, composition, and technological properties, and strategies to reduce adverse reactions. *Compr. Rev. Food Sci. Food Saf.* **2019**, *18*, 1751–1769.
30. Rustgi, S.; Wen, N.; Osorio, C.; Brew-Appiah, R.A.T.; Wen, S.; Gemini, R.; Mejias, J.H.; Ankrah, N.; Moehs, C.P.; von Wettstein, D. *Natural Dietary Therapies for the 'Gluten Syndrome'*; The Royal Danish Academy of Sciences and Letters: Copenhagen, Denmark, 2014; p. 87.
31. Sapone, A.; Bai, J.C.; Ciacci, C.; Dolinsek, J.; Green, P.H.; Hadjivassiliou, M.; Kaukinen, K.; Rostami, K.; Sanders, D.S.; Schumann, M.; et al. Spectrum of gluten-related disorders: Consensus on new nomenclature and classification. *BMC Med.* **2012**, *10*, 13.
32. Schoft, V.K.; Chumak, N.; Choi, Y.; Hannon, M.; Garcia-Aguilar, M.; Machlicova, A.; Slusarz, L.; Mosiolek, M.; Park, J.S.; Park, G.T.; et al. Function of the DEMETER DNA glycosylase in the *Arabidopsis thaliana* male gametophyte. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 8042–8047.
33. Shah, F.; Shi, A.; Ashley, J.; Kronfel, C.; Wang, Q.; Maleki, S.J.; Adhikari, B.; Zhang, J. Peanut allergy: Characteristics and approaches for mitigation. *Compr. Rev. Food Sci. Food Saf.* **2019**, *18*, 1361–1387.
34. Shewry, P. What is gluten-why is it special? *Front. Nutr.* **2019**, *6*, 101.
35. Singh, P.; Arora, A.; Strand, T.A.; Leffler, D.A.; Catassi, C.; Green, P.H.; Kelly, C.P.; Ahuja, V.; Makharia, G.K. Global prevalence of celiac disease: Systematic review and meta-analysis. *Clin. Gastroenterol. Hepatol.* **2018**, *16*, 823–836.
36. Stalker, H.T. Utilizing wild species for peanut improvement. *Crop. Sci.* **2017**, *57*, 1102–1120.
37. US Food & Drug Administration. Food Allergies. 2021. Available online: <https://www.fda.gov/food/food-labeling-nutrition/food-allergies> (accessed on February 16, 2022).
38. Vickery, B.P.; Vereda, A.; Casale, T.B.; Beyer, K.; du Toit, G.; Hourihane, J.O.; Jones, S.M.; Shreffler, W.G.; Marcantonio, A.; Zawadzki, R.; et al. AR101 oral immunotherapy for peanut allergy. *N. Engl. J. Med.* **2018**, *379*, 1991–2001.
39. Wang, D.; Li, F.; Cao, S.; Zhang, K. Genomic and functional genomics analyses of gluten proteins and prospect for simultaneous improvement of end-use and health-related traits in wheat. *Theor. Appl. Genet.* **2020**, *133*, 1521–1539.
40. Warren, C.; Lei, D.; Sicherer, S.; Schleimer, R.; Gupta, R. Prevalence and characteristics of peanut allergy in US adults. *J. Allergy Clin. Immunol.* **2021**, *147*, 2263–2270.
41. Wen, N.; Osorio, C.E.; Brew-Appiah, R.A.T.; Mejias, J.H.; Alam, T.; Kashyap, S.; Reinbothe, S.; Reinbothe, C.; Moehs, C.P.; von Wettstein, D.; Rustgi, S. Targeting Induced Local Lesions in the wheat *DEMETER* and *DRE2* genes, responsible for transcriptional derepression of wheat gluten proteins in the developing endosperm. *Front. Nutr.* **2022**, *9*, 847635.
42. Wen, S.; Wen, N.; Pang, J.; Langen, G.; Brew-Appiah, R.A.T.; Mejias, J.H.; Osorio, C.; Yang, M.M.; Gemini, R.; Moehs, C.P.; et al. Structural genes of wheat and barley 5-methylcytosine DNA glycosylases and their potential applications for human health. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 20543–20548.
43. Windham, J.; Sharma, S.; Kashyap, M.K.; Rustgi, S. CRISPR/Cas12a (Cpf1) and its role in plant genome editing. In *RNA-Based Technologies for Functional Genomics in Plants*; Tang, G., Teotia, S., Tang, X., Singh, D., Eds.; Springer Nature: Cham, Switzerland, 2021, pp. 15–42.
44. World—Wheat Area Harvested. 2020. Available online: <https://knoema.com/atlas/World/topics/Agriculture/Crops-Production-Area-Harvested/Wheat-area-harvested> (accessed on February 16, 2022).
45. Yu, J.; Ahmedna, M.; Goktepe, I.; Cheng, H.; Maleki, S. Enzymatic treatment of peanut kernels to reduce allergen levels. *Food Chem.* **2011**, *127*, 1014–1022.